Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas
that do not respond to treatment (refractory) and have spread to other parts of the body
(advanced/metastatic). Itacitinib may cause changes in the immune system and the body's
immune response to cancer, which may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Incyte Corporation National Cancer Institute (NCI)